u/milos_mensa

the pharmacy and the prescriber are two separate questions

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

Right, and reading the actual supply notice rather than the coverage of it saves a fortnight of speculation.

Nothing on this board is legal advice. Where a notice carries a deadline or a consequence, that is a matter for somebody qualified in your own jurisdiction.

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

Kept every document including the dull ones. When a process started, having the dates in order made it short.

Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.

How long have you been on the list, and from what date?

Cosigning on paperwork. The boring documents are the ones that matter when a process starts.

A log is only interpretable if the conditions are consistent. Same day, same time, same state, same scale — otherwise you are recording measurement variability rather than change.

Is this a discharge back to the GP, or a discontinuation?

Which nation, and which ICB if you are in England?

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

the shortage list is the whole legal hinge and people skip it

The rules where I live changed between two orders six months apart. Nothing was announced; I found out by reading.

Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.

Choose a format you will still be able to open in two years. Plain text or a spreadsheet you export beats an application that may not exist.

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

Small fix — that is the Scottish pathway.

halima_boateng is right that the two routes are separate. A private prescription does not move you up the list.

Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.

the ICB decides the threshold and they are not the same across England

Pharmacy pricing on a private prescription is set by the pharmacy. The spread between them in a given month is routinely substantial, which is why a tracker built from member reports is more useful than any headline.

Same. Very thin independent data on this one, which should make everybody here more tentative than they are.

Agreed. The ICB variation is the thing that makes national advice useless here.

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

A log is a record of what you did. It is not a protocol, and posting one as a schedule for other members is a different thing that this board does not do.

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

GP said no in the spring, specialist said yes eighteen months later. Same person, same numbers.

Right, and the trial titration was slow for reasons that are visible in the tolerability tables.

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

Have you seen the current threshold published by your ICB?

Yes — the rodent literature is real and it is rodent literature. The gap to a human claim is enormous and it gets crossed in one sentence here.

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

the weight numbers are secondary to what this is being developed for

a 503B has to register and report, so there is a paper trail to ask for

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

What did the intake actually ask you?

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

nothing in this board is legal advice

escrow_evangelist is right that regional stock is the structural answer rather than a trick.